EU approves Novartis Tafinlar + Mekinist combination for NSCLC treatment

This article was originally published here

Novartis’ drug combination of Tafinlar (dabrafenib) and Mekinist (trametinib) has been approved by the European Commission for the treatment of patients having BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply